|
1
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schulz R, Streller F, Scheel AH, Rüschoff
J, Reinert MC, Dobbelstein M, Marchenko ND and Moll UM: HER2/ErbB2
activates HSF1 and thereby controls HSP90 clients including MIF in
HER2-overexpressing breast cancer. Cell Death Dis. 5:e9802014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nahta R: Molecular mechanisms of
trastuzumab-based treatment in HER2-overexpressing breast cancer.
ISRN Oncol. 2012:4280622012.PubMed/NCBI
|
|
5
|
Gelmon KA, Boyle FM, Kaufman B, Huntsman
DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J,
Aparicio S, et al: Lapatinib or trastuzumab plus taxane therapy for
human epidermal growth factor receptor 2-positive advanced breast
cancer: Final results of NCIC CTG MA.31. J Clin Oncol.
33:1574–1583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valero V, Forbes J, Pegram MD, Pienkowski
T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey
JR, et al: Multicenter phase III randomized trial comparing
docetaxel and trastuzumab with docetaxel, carboplatin, and
trastuzumab as first-line chemotherapy for patients with
HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two
highly active therapeutic regimens. J Clin Oncol. 29:149–156. 2011.
View Article : Google Scholar
|
|
7
|
Ritter CA, Perez-Torres M, Rinehart C,
Guix M, Dugger T, Engelman JA and Arteaga CL: Human breast cancer
cells selected for resistance to trastuzumab in vivo overexpress
epidermal growth factor receptor and ErbB ligands and remain
dependent on the ErbB receptor network. Clin Cancer Res.
13:4909–4919. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Madrid-Paredes A, Cañadas-Garre M,
Sánchez-Pozo A and Calleja-Hernández MA: Non-HER2 signaling
pathways activated in resistance to anti-HER2 therapy in breast
cancer. Breast Cancer Res Treat. 153:493–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scaltriti M, Rojo F, Ocaña A, Anido J,
Guzman M, Cortes J, D Cosimo S, Matias-Guiu X, Ramon y Cajal S,
Arribas J, et al: Expression of p95HER2, a truncated form of the
HER2 receptor, and response to anti-HER2 therapies in breast
cancer. J Natl Cancer Inst. 99:628–638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ozkavruk Eliyatkin N, Aktas S, Ozgur H,
Ercetin P and Kupelioglu A: The role of p95HER2 in trastuzumab
resistance in breast cancer. J BUON. 21:382–389. 2016.PubMed/NCBI
|
|
11
|
Narayan M, Wilken JA, Harris LN, Baron AT,
Kimbler KD and Maihle NJ: Trastuzumab-induced HER reprogramming in
'resistant' breast carcinoma cells. Cancer Res. 69:2191–2194. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deguchi Y, Okabe H, Oshima N, Hisamori S,
Minamiguchi S, Muto M and Sakai Y: PTEN loss is associated with a
poor response to trastuzumab in HER2-overexpressing
gastroesophageal adenocarcinoma. Gastric Cancer. 20:416–427. 2017.
View Article : Google Scholar
|
|
13
|
Luque-Cabal M, García-Teijido P,
Fernández-Pérez Y, Sánchez-Lorenzo L and Palacio-Vázquez I:
Mechanisms behind the resistance to Trastuzumab in HER2-amplified
breast cancer and strategies to overcome it. Clin Med Insights
Oncol. 10(Suppl 1): 21–30. 2016.PubMed/NCBI
|
|
14
|
Liu J, Pan C, Guo L, Wu M, Guo J, Peng S,
Wu Q and Zuo Q: A new mechanism of trastuzumab resistance in
gastric cancer: MACC1 promotes the Warburg effect via activation of
the PI3K/AKT signaling pathway. J Hematol Oncol. 9:762016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jura N, Shan Y, Cao X, Shaw DE and Kuriyan
J: Structural analysis of the catalytically inactive kinase domain
of the human EGF receptor 3. Proc Natl Acad Sci USA.
106:21608–21613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi F, Telesco SE, Liu Y, Radhakrishnan R
and Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind
ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA.
107:7692–7697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee-Hoeflich ST, Crocker L, Yao E, Pham T,
Munroe X, Hoeflich KP, Sliwkowski MX and Stern HM: A central role
for HER3 in HER2-amplified breast cancer: Implications for targeted
therapy. Cancer Res. 68:5878–5887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeong H, Kim J, Lee Y, Seo JH, Hong SR and
Kim A: Neuregulin-1 induces cancer stem cell characteristics in
breast cancer cell lines. Oncol Rep. 32:1218–1224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheng Q, Liu X, Fleming E, Yuan K, Piao H,
Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, et al: An
activated ErbB3/NRG1 autocrine loop supports in vivo proliferation
in ovarian cancer cells. Cancer Cell. 17:298–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Boeck A, Pauwels P, Hensen K, Rummens
JL, Westbroek W, Hendrix A, Maynard D, Denys H, Lambein K, Braems
G, et al: Bone marrow-derived mesenchymal stem cells promote
colorectal cancer progression through paracrine neuregulin 1/HER3
signalling. Gut. 62:550–560. 2013. View Article : Google Scholar
|
|
21
|
Kim S, Han J, Shin I, Kil WH, Lee JE and
Nam SJ: A functional comparison between the HER2(high)/HER3 and the
HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9
expression in breast cancer cells. Exp Mol Med. 44:473–482. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Göstring L, Malm M, Höidén-Guthenberg I,
Frejd FY, Ståhl S, Löfblom J and Gedda L: Cellular effects of
HER3-specific affibody molecules. PLoS One. 7:e400232012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ni M, Chen Y, Lim E, Wimberly H, Bailey
ST, Imai Y, Rimm DL, Liu XS and Brown M: Targeting androgen
receptor in estrogen receptor-negative breast cancer. Cancer Cell.
20:119–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shim JS, Rao R, Beebe K, Neckers L, Han I,
Nahta R and Liu JO: Selective inhibition of HER2-positive breast
cancer cells by the HIV protease inhibitor nelfinavir. J Natl
Cancer Inst. 104:1576–1590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barok M, Tanner M, Köninki K and Isola J:
Trastuzumab-DM1 causes tumour growth inhibition by mitotic
catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Breast Cancer Res. 13:R462011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Walsh AJ, Cook RS, Sanders ME, Aurisicchio
L, Ciliberto G, Arteaga CL and Skala MC: Quantitative optical
imaging of primary tumor organoid metabolism predicts drug response
in breast cancer. Cancer Res. 74:5184–5194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Q, Yuan Z and Cao B: The function of
human epidermal growth factor receptor-3 and its role in tumors
(Review). Oncol Rep. 30:2563–2570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garrett JT, Sutton CR, Kuba MG, Cook RS
and Arteaga CL: Dual blockade of HER2 in HER2-overexpressing tumor
cells does not completely eliminate HER3 function. Clin Cancer Res.
19:610–619. 2013. View Article : Google Scholar :
|
|
29
|
Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V,
Kraft P, Kim S, Gao Y, Pak J, et al: Downregulation of HER3 by a
novel antisense oligonucleotide, EZN-3920, improves the antitumor
activity of EGFR and HER2 tyrosine kinase inhibitors in animal
models. Mol Cancer Ther. 12:427–437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ebbing EA, Medema JP, Damhofer H, Meijer
SL, Krishnadath KK, van Berge Henegouwen MI, Bijlsma MF and van
Laarhoven HW: ADAM10-mediated release of heregulin confers
resistance to trastuzumab by activating HER3. Oncotarget.
7:10243–10254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leung WY, Roxanis I, Sheldon H, Buffa FM,
Li JL, Harris AL and Kong A: Combining lapatinib and pertuzumab to
overcome lapatinib resistance due to NRG1-mediated signalling in
HER2-amplified breast cancer. Oncotarget. 6:5678–5694. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xia W, Petricoin EF III, Zhao S, Liu L,
Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, et
al: An heregulin-EGFR-HER3 autocrine signaling axis can mediate
acquired lapatinib resistance in HER2+ breast cancer
models. Breast Cancer Res. 15:R852013. View Article : Google Scholar
|
|
33
|
Dey N, Sun Y, Carlson JH, Wu H, Lin X,
Leyland-Jones B and De P: Anti-tumor efficacy of BEZ235 is
complemented by its anti-angiogenic effects via downregulation of
PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J
Cancer Res. 6:714–746. 2016.PubMed/NCBI
|
|
34
|
Crafter C, Vincent JP, Tang E, Dudley P,
James NH, Klinowska T and Davies BR: Combining AZD8931, a novel
EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT
inhibitor induced feedback and enhances antitumour efficacy in
HER2-amplified breast cancer models. Int J Oncol. 47:446–454. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
O'Brien NA, McDonald K, Tong L, von Euw E,
Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz
R, et al: Targeting PI3K/mTOR overcomes resistance to HER2-targeted
therapy independent of feedback activation of AKT. Clin Cancer Res.
20:3507–3520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Merry CR, McMahon S, Forrest ME, Bartels
CF, Saiakhova A, Bartel CA, Scacheri PC, Thompson CL, Jackson MW,
Harris LN, et al: Transcriptome-wide identification of mRNAs and
lincRNAs associated with trastuzumab-resistance in HER2-positive
breast cancer. Oncotarget. 7:53230–53244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kawakami H, Okamoto I, Yonesaka K, Okamoto
K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K,
et al: The anti-HER3 antibody patritumab abrogates cetuximab
resistance mediated by heregulin in colorectal cancer cells.
Oncotarget. 5:11847–11856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Duan Y, Qiao C, Zhou T, Yu M, Geng
J, Feng J, Shen B, Lv M and Li Y: Anti-HER3 monoclonal antibody
inhibits acquired trastuzumab-resistant gynecologic cancers.
Technol Cancer Res Treat. 15:573–582. 2016. View Article : Google Scholar
|
|
39
|
Wang Q, Zhang X, Shen E, Gao J, Cao F,
Wang X, Li Y, Tian T, Wang J, Chen Z, et al: The anti-HER3 antibody
in combination with trastuzumab exerts synergistic antitumor
activity in HER2-positive gastric cancer. Cancer Lett. 380:20–30.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Canonici A, Gijsen M, Mullooly M, Bennett
R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E,
et al: Neratinib overcomes trastuzumab resistance in HER2 amplified
breast cancer. Oncotarget. 4:1592–1605. 2013. View Article : Google Scholar : PubMed/NCBI
|
